Product Image

Contributor Information

  • Name George Stark ; Ian Kerr
  • Institute Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details

  • Tool name: 2C4-Gamma2A cell line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: 2C4 cell line (a derivative of HT 1080 cell line)
  • Organism: Human
  • Cancer type: Fibrosarcoma
  • Disease: Cancer
  • Description: Mutant gamma2A cells retain a wild-type interferon (IFN)-alpha/beta response (e.g., class I HLA Binding of IFN-gamma to gamma2A cells is normal), but the cells lack detectable JAK2 mRNA and protein and are completely defective in all aspects of the IFN-gamma response. More specifically, they are defective in IFN-gamma inducible activation of the JAK/STAT pathway, gene expression, and an antiviral state with respect to encephalomyocarditis (EMC) virus. In all cases, JAK2 (but not JAK1 or Tyk2 restores a wild-type phenotype. The gamma2A mutant cells lack inducible phosphorylation of the IFN-gamma receptor 1 (R1) subunit, JAK1, and STAT1 and IFN-gamma-inducible cell surface expression of class I and II HLAs. In each case, the wild-type IFN-gamma response is restored in gamma2A/JAK2 transfectants (Kohlhuber et al., 1997).
  • Research area: Cell Signaling & Signal Transduction ; Gene Expression ; Immunology

  • For Research Use Only

Target Details

Application Details

Handling

  • Format: Frozen
  • Growth medium: DMEM + 10% heat-inactivated FBS + 400ug G418 per ml
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

  • Available on request

References

  •   Kohlhuber et al. 1997. Mol Cell Biol. 17(2):695-706. PMID: 9001223.
  •   A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.
  •   Watling et al. 1993. Nature. 366(6451):166-70. PMID: 7901766.
  •   Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway.